We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest market close, Medpace (MEDP - Free Report) reached $343.38, with a -1.65% movement compared to the previous day. This move lagged the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.28%, and the tech-heavy Nasdaq lost 1.2%.
The the stock of provider of outsourced clinical development services has risen by 2.85% in the past month, lagging the Medical sector's gain of 8.26% and overreaching the S&P 500's gain of 2.71%.
The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is scheduled to release its earnings on February 10, 2025. On that day, Medpace is projected to report earnings of $2.97 per share, which would represent year-over-year growth of 20.73%. Our most recent consensus estimate is calling for quarterly revenue of $536.37 million, up 7.62% from the year-ago period.
Investors should also pay attention to any latest changes in analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Medpace holds a Zacks Rank of #2 (Buy).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 28.11. This expresses a premium compared to the average Forward P/E of 17.74 of its industry.
Also, we should mention that MEDP has a PEG ratio of 1.79. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MEDP's industry had an average PEG ratio of 1.72 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 149, finds itself in the bottom 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medpace (MEDP) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest market close, Medpace (MEDP - Free Report) reached $343.38, with a -1.65% movement compared to the previous day. This move lagged the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.28%, and the tech-heavy Nasdaq lost 1.2%.
The the stock of provider of outsourced clinical development services has risen by 2.85% in the past month, lagging the Medical sector's gain of 8.26% and overreaching the S&P 500's gain of 2.71%.
The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is scheduled to release its earnings on February 10, 2025. On that day, Medpace is projected to report earnings of $2.97 per share, which would represent year-over-year growth of 20.73%. Our most recent consensus estimate is calling for quarterly revenue of $536.37 million, up 7.62% from the year-ago period.
Investors should also pay attention to any latest changes in analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Medpace holds a Zacks Rank of #2 (Buy).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 28.11. This expresses a premium compared to the average Forward P/E of 17.74 of its industry.
Also, we should mention that MEDP has a PEG ratio of 1.79. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MEDP's industry had an average PEG ratio of 1.72 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 149, finds itself in the bottom 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.